Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fuji
UBS
QuintilesIMS
Baxter
Citi
Federal Trade Commission
Dow
Medtronic

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,883,836

« Back to Dashboard

Which drugs does patent 8,883,836 protect, and when does it expire?

Patent 8,883,836 protects TREANDA and is included in one NDA.

Protection for TREANDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixteen patent family members in ten countries.
Summary for Patent: 8,883,836
Title:Solid forms of bendamustine hydrochloride
Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
Inventor(s): Cooper; Martin Ian (Cambridge, GB), Courvoisier; Laurent D. (Thorndale, PA), Eddleston; Mark (Nottingham, GB), McKean; Robert E. (Chester Springs, PA)
Assignee: Cephalon, Inc. (Frazer, PA)
Application Number:14/200,738
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,883,836
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process;

Drugs Protected by US Patent 8,883,836

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cephalon TREANDA bendamustine hydrochloride POWDER;IV (INFUSION) 022249-002 May 1, 2009 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Cephalon TREANDA bendamustine hydrochloride POWDER;IV (INFUSION) 022249-001 Mar 20, 2008 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,883,836

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,533,955 Solid forms of bendamustine hydrochloride ➤ Try a Free Trial
8,445,524 Solid forms of bendamustine hydrochloride ➤ Try a Free Trial
8,669,279 Solid forms of bendamustine hydrochloride ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,883,836

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 072777 ➤ Try a Free Trial
Canada 2718939 ➤ Try a Free Trial
China 101980698 ➤ Try a Free Trial
China 103550159 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Queensland Health
Deloitte
QuintilesIMS
Federal Trade Commission
Dow
Healthtrust
Argus Health
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.